har power immune system recon limit cancer cell longtime explore past dead monoclonal antibody abbas checkpoint blocked icb chime antigen receptor cart cell therapy proven safe effect hematolog align despite unplaced success subset patient benefit partial due defunct lack appropri target review prelim clinic advance cola pdlpdbase cdspecif also discus basic research onto trial emerge checkpoint galectintim ccd lag lib new cd bca treatment 